HCW Biologics Inc（HCWB）のニュースとイベントHCWBHCW Biologics Inc

HCW Biologics Receives Patent Allowance for HCW9302 in Treating Alopecia Areata

HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata. Together with four other recently issued patents with claims for broad compositions, nucleic acids encoding for HCW9302 and the vectors comprising these, and method of treating other autoimmune diseases, the underlying U.S. patent estate has been further strengthened for the protection of the company's intellectual property related to further development and potential commercialization of HCW9302, a best-in-class IL-2-based immunotherapeutic for the treatment of autoimmune diseases. The company continues to extend protection of its broad rights for treatments for all indications with respect to HCW9302 built on the foundation of its worldwide, perpetual, fully paid-up, royalty-free, exclusive license rights for this compound. The Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata is on track for completion in Q4 2026, and continues to be well tolerated with no dose-limiting toxicities. A preliminary readout of the first two dose cohorts is encouraging, with patients diagnosed with alopecia areata showing positive response after a single dose of monotherapy at the 3 micrograms/kg dose level.

Selling Stockholders Plan to Sell 1.24M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.24M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

HCW Biologics Completes $1.6M Private Placement

HCW Biologics announced the pricing of its $1.6M private placement offering with a group of investors, including officers, directors and an existing stockholder of the company. Pursuant to a securities purchase agreement entered into with the Investors, the company agreed to issue and sell an aggregate of 618,682 units, with each Unit consisting of (i) one share of the company's common stock, or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock, and (ii) the right to receive one common stock purchase warrant to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance thereof. In connection with the Offering, the company will issue 218,682 shares of Common Stock and 400,000 Pre-Funded Warrants. Subject to stockholder approval, which the company is obligated to seek pursuant to the terms of the Purchase Agreement, the Investors will also be entitled to receive Common Warrants to purchase up to an aggregate of 618,682 shares of Common Stock. The combined purchase price for each Unit consisting of one share of Common Stock and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $2.585 per Unit. The combined purchase price for a Pre-Funded Warrant and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $2.5849 per Unit. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock, are exercisable immediately and will not expire until exercised in full. The Common Warrants will have an exercise price of $2.585 per share and will expire on the five and one half year anniversary of their issuance.